193 related articles for article (PubMed ID: 15728459)
1. Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma.
Jeffes EW; Zhang JG; Hoa N; Petkar A; Delgado C; Chong S; Obenaus A; Sanchez R; Khalaghizadeh S; Khomenko T; Knight BA; Alipanah R; Nguyen TV; Shah C; Vohra S; Zhuang JL; Liu J; Wepsic HT; Jadus MR
J Immunol; 2005 Mar; 174(5):2533-43. PubMed ID: 15728459
[TBL] [Abstract][Full Text] [Related]
2. T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas.
Sanchez R; Williams C; Daza JL; Dan Q; Xu Q; Chen Y; Delgado C; Arpajirakul N; Jeffes EW; Kim RC; Douglass T; Al Atar U; Terry Wepsic H; Jadus MR
Cell Immunol; 2002 Jan; 215(1):1-11. PubMed ID: 12142031
[TBL] [Abstract][Full Text] [Related]
3. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
4. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination.
Graf MR; Prins RM; Hawkins WT; Merchant RE
Cancer Immunol Immunother; 2002 Jun; 51(4):179-89. PubMed ID: 12012105
[TBL] [Abstract][Full Text] [Related]
5. Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"-induced pathway that promotes systemic immunity against intracranial T9 gliomas.
Chen Y; Douglass T; Jeffes EW; Xu Q; Williams CC; Arpajirakul N; Delgado C; Kleinman M; Sanchez R; Dan Q; Kim RC; Wepsic HT; Jadus MR
Blood; 2002 Aug; 100(4):1373-80. PubMed ID: 12149220
[TBL] [Abstract][Full Text] [Related]
6. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
Okada H; Villa L; Attanucci J; Erff M; Fellows WK; Lotze MT; Pollack IF; Chambers WH
Gene Ther; 2001 Aug; 8(15):1157-66. PubMed ID: 11509946
[TBL] [Abstract][Full Text] [Related]
7. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine.
Okada H; Giezeman-Smits KM; Tahara H; Attanucci J; Fellows WK; Lotze MT; Chambers WH; Bozik ME
Gene Ther; 1999 Feb; 6(2):219-26. PubMed ID: 10435106
[TBL] [Abstract][Full Text] [Related]
8. Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas.
Graf MR; Sauer JT; Merchant RE
J Neurooncol; 2005 May; 73(1):29-36. PubMed ID: 15933813
[TBL] [Abstract][Full Text] [Related]
9. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of human recombinant macrophage colony-stimulating factor against rat brain tumors.
Matsuoka T; Uozumi T; Kurisu K; Maeda H; Kawamoto K; Monden S
Biotherapy; 1994; 8(1):51-62. PubMed ID: 7547081
[TBL] [Abstract][Full Text] [Related]
11. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression.
Prins RM; Scott GP; Merchant RE; Graf MR
Cancer Immunol Immunother; 2002 Jun; 51(4):190-9. PubMed ID: 12012106
[TBL] [Abstract][Full Text] [Related]
12. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
Clavreul A; Delhaye M; Jadaud E; Menei P
J Neurooncol; 2006 Aug; 79(1):9-17. PubMed ID: 16575532
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2.
Machein MR; Risau W; Plate KH
Hum Gene Ther; 1999 May; 10(7):1117-28. PubMed ID: 10340544
[TBL] [Abstract][Full Text] [Related]
14. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
15. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
16. Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer.
Williams CC; Trinh H; Tran TV; Dan Q; Sanchez R; Delgado C; Chen Y; Sippel B; Jeffes EW; Wepsic HT; Jadus MR
Mol Ther; 2001 Feb; 3(2):216-24. PubMed ID: 11237678
[TBL] [Abstract][Full Text] [Related]
17. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.
Laterra J; Nam M; Rosen E; Rao JS; Lamszus K; Goldberg ID; Johnston P
Lab Invest; 1997 Apr; 76(4):565-77. PubMed ID: 9111517
[TBL] [Abstract][Full Text] [Related]
18. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor.
Graf MR; Jadus MR; Hiserodt JC; Wepsic HT; Granger GA
J Immunol; 1999 Nov; 163(10):5544-51. PubMed ID: 10553082
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
[TBL] [Abstract][Full Text] [Related]
20. MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model.
Herrlinger U; Aulwurm S; Strik H; Weit S; Naumann U; Weller M
J Neurooncol; 2004 Jan; 66(1-2):147-54. PubMed ID: 15015780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
